ReEngage Therapeutics is a biopharmaceutical research and development company dedicated to creating innovative treatments for longevity-related diseases, particularly those associated with aging, such as neurodegeneration and cancer. The company focuses on modifying epigenetic targets that play a significant role in these aging-related disorders. A key aspect of their research involves the exclusive licensing of ACSS2 inhibitors from Epivario Inc., which are being explored for their potential in cancer treatment. ReEngage is also engaged in collaborative research efforts with prominent institutions, including a sponsored research agreement with MD Anderson, led by Dr. Eyal Gottlieb, and a partnership with the Scripps Florida high-throughput screening team.

The company is actively advancing its pipeline of ACSS2 inhibitor compounds aimed at various cancer indications. Recent developments include joining the Texas Medical Center’s 2025 Accelerator for Cancer Therapeutics and launching initiatives to accelerate the development of these inhibitors as viable cancer therapies. Through these strategic collaborations and focused research efforts, ReEngage Therapeutics is positioned to make significant contributions to the field of longevity and age-related disease treatment.

United States

ReEngage is a biopharmaceutical R&D company focused on developing drugs that treat longevity-related diseases.  ReEngage does this by modifying epigenetic targets that are implicated in aging-related disorders, including neurodegeneration and cancer.

ReEngage Therapeutics

Company Details